Pat R. Brady
Direttore/Membro del Consiglio presso Twinstrand Therapeutics, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Daniel J. Wattier | M | - |
Valocor Therapeutics, Inc.
Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist. | - |
Thor J. Borgford | M | - |
Twinstrand Therapeutics, Inc.
Twinstrand Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Twinstrand Therapeutics Inc. manufactures and distributes biological drugs. It focuses on discovering, developing and commercializing of therapeutics for the treatment of cancer, hepatitis A, cytomegalovirus, malaria, schistosomiasis, and fungal diseases. The company was founded in 1995 and is located in North Vancouver, Canada. | 29 anni |
Julia G. Levy | M | 89 |
Valocor Therapeutics, Inc.
Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist.
Twinstrand Therapeutics, Inc.
Twinstrand Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Twinstrand Therapeutics Inc. manufactures and distributes biological drugs. It focuses on discovering, developing and commercializing of therapeutics for the treatment of cancer, hepatitis A, cytomegalovirus, malaria, schistosomiasis, and fungal diseases. The company was founded in 1995 and is located in North Vancouver, Canada. | - |
David Hunt | M | - |
Valocor Therapeutics, Inc.
Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist. | - |
Agnes Chan | M | - |
Valocor Therapeutics, Inc.
Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist. | - |
Robert A. Fildes | M | 85 |
Twinstrand Therapeutics, Inc.
Twinstrand Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Twinstrand Therapeutics Inc. manufactures and distributes biological drugs. It focuses on discovering, developing and commercializing of therapeutics for the treatment of cancer, hepatitis A, cytomegalovirus, malaria, schistosomiasis, and fungal diseases. The company was founded in 1995 and is located in North Vancouver, Canada. | - |
Curtis A. Braun | M | - |
Twinstrand Therapeutics, Inc.
Twinstrand Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Twinstrand Therapeutics Inc. manufactures and distributes biological drugs. It focuses on discovering, developing and commercializing of therapeutics for the treatment of cancer, hepatitis A, cytomegalovirus, malaria, schistosomiasis, and fungal diseases. The company was founded in 1995 and is located in North Vancouver, Canada. | 28 anni |
Jeanne M. Bertonis | F | - |
Twinstrand Therapeutics, Inc.
Twinstrand Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Twinstrand Therapeutics Inc. manufactures and distributes biological drugs. It focuses on discovering, developing and commercializing of therapeutics for the treatment of cancer, hepatitis A, cytomegalovirus, malaria, schistosomiasis, and fungal diseases. The company was founded in 1995 and is located in North Vancouver, Canada. | - |
Marjorie Co | F | 54 |
Twinstrand Therapeutics, Inc.
Twinstrand Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Twinstrand Therapeutics Inc. manufactures and distributes biological drugs. It focuses on discovering, developing and commercializing of therapeutics for the treatment of cancer, hepatitis A, cytomegalovirus, malaria, schistosomiasis, and fungal diseases. The company was founded in 1995 and is located in North Vancouver, Canada. | 19 anni |
Donna Parr | F | - |
Twinstrand Therapeutics, Inc.
Twinstrand Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Twinstrand Therapeutics Inc. manufactures and distributes biological drugs. It focuses on discovering, developing and commercializing of therapeutics for the treatment of cancer, hepatitis A, cytomegalovirus, malaria, schistosomiasis, and fungal diseases. The company was founded in 1995 and is located in North Vancouver, Canada. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Cameron Lawrence | M | 44 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 4 anni |
Stephen Charles Anderson | M | 61 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 2 anni |
Cindy Jacobs | M | 66 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Canada | 10 | 76.92% |
Stati Uniti | 3 | 23.08% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Pat R. Brady
- Contatti personali